Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss

Novo Nordisk’s pill is an oral version of semaglutide, the active ingredient in the Danish company’s blockbuster weight loss injections Ozempic and Wegovy.

Previous post Pfizer to end development of experimental obesity pill due to elevated liver enzymes
Next post Storms, air traffic control facility delay thousands of flights